Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia.
BACKGROUND
Raised plasma lipoprotein(a) (Lp(a)) is associated with increased risk of cardiovascular disease. It is unknown whether increased Lp(a) is an additional risk factor for coronary artery disease in familial hypercholesterolaemia (FH) or whether statin treatment can reduce Lp(a) concentrations in the long term.


OBJECTIVE
To investigate Lp(a) concentrations in relation to statin treatment and the progression of atherosclerosis in a large cohort of FH patients.


METHODS
A two year, randomised, double blind trial (the ASAP trial).


METHODS
325 heterozygous FH patients.


METHODS
Treatment with 80 mg atorvastatin or 40 mg simvastatin.


METHODS
Change in Lp(a) concentrations and intima-media thickness of carotid artery segments at one year and two years.


RESULTS
At baseline, median Lp(a) concentrations were 327 mg/l and 531 mg/l in the atorvastatin and simvastatin arms, respectively (p = 0.03). In the atorvastatin arm, Lp(a) concentrations decreased to 243 mg/l after one year (p < 0.001) and to 263 mg/l after two years (p < 0.001). In the simvastatin arm, Lp(a) concentrations decreased to 437 mg/l after one year (p < 0.001) and to 417 mg/l after two years (p < 0.001). The difference in Lp(a) reduction between the two treatment arms was significant after one year (p = 0.004), but not after two years (p = 0.086). Lp(a) concentrations at baseline were not related to cardiovascular events at baseline. There was no correlation between baseline Lp(a) concentrations and low density lipoprotein cholesterol concentrations or intima-media thickness at baseline. Change in Lp(a) concentrations was not correlated with change in intima-media thickness after one or two years.


CONCLUSIONS
Long term statin treatment significantly lowers Lp(a) in FH patients. However, this reduction was unrelated to changes in intima-media thickness and casts doubt on the importance of Lp(a) in the progression of atherosclerotic disease in these patients.
van Wissen
S
S
Department of Vascular Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands. s.vanwissen@amc.uva.nl
Smilde
T J
TJ
Trip
M D
MD
de Boo
Th
T
Kastelein
J J P
JJ
Stalenhoef
A F H
AF
D001161:Arteriosclerosis / Q000517:prevention & control*; D000069059:Atorvastatin; D002339:Carotid Arteries; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy*; D017270:Lipoprotein(a) / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000627:therapeutic use*; D019821:Simvastatin / Q000627:therapeutic use*
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017270:Lipoprotein(a); D011758:Pyrroles; D000069059:Atorvastatin; D019821:Simvastatin